

# Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media

Matthew Bauler,<sup>1</sup> Jessica K. Roberts,<sup>1,4</sup> Chang-Chih Wu,<sup>1,5</sup> Baochang Fan,<sup>2</sup> Francesca Ferrara,<sup>1</sup> Bon Ham Yip,<sup>1</sup> Shiyong Diao,<sup>1</sup> Young-In Kim,<sup>3</sup> Jennifer Moore,<sup>3</sup> Sheng Zhou,<sup>3</sup> Matthew M. Wielgosz,<sup>1</sup> Byoung Ryu,<sup>1,5</sup> and Robert E. Throm<sup>1</sup>

<sup>1</sup>Vector Development and Production Laboratory, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; <sup>2</sup>Therapeutics Production and Quality, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; <sup>3</sup>Experimental Cell Therapeutics Lab, St. Jude Children's Research Hospital, Memphis, TN 38105, USA

**Lentiviral vectors are increasingly utilized in cell and gene therapy applications because they efficiently transduce target cells such as hematopoietic stem cells and T cells. Large-scale production of current Good Manufacturing Practices-grade lentiviral vectors is limited because of the adherent, serum-dependent nature of HEK293T cells used in the manufacturing process. To optimize large-scale clinical-grade lentiviral vector production, we developed an improved production scheme by adapting HEK293T cells to grow in suspension using commercially available and chemically defined serum-free media. Lentiviral vectors with titers equivalent to those of HEK293T cells were produced from SJ293TS cells using optimized transfection conditions that reduced the required amount of plasmid DNA by 50%. Furthermore, purification of SJ293TS-derived lentiviral vectors at 1 L yielded a recovery of 55% ± 14% (n = 138) of transducing units in the starting material, more than a 2-fold increase over historical yields from adherent HEK293T serum-dependent lentiviral vector preparations. SJ293TS cells were stable to produce lentiviral vectors over 4 months of continuous culture. SJ293TS-derived lentiviral vectors efficiently transduced primary hematopoietic stem cells and T cells from healthy donors. Overall, our SJ293TS cell line enables high-titer vector production in serum-free conditions while reducing the amount of input DNA required, resulting in a highly efficient manufacturing option.**

## INTRODUCTION

HIV-1-derived lentiviral vectors (LVs) are efficient gene transfer vehicles used in both basic and clinical research settings. The ability of LVs to efficiently shuttle DNA into mammalian cells enables researchers to explore the function of various genes of interest.<sup>1–5</sup> Clinically, LVs are used *ex vivo* to deliver therapeutic genes or expression cassettes to primary target cells, such as hematopoietic stem cells (HSCs), to treat genetic disorders or infectious diseases.<sup>6–9</sup> LVs are well suited for use in *ex vivo* gene therapy because they can deliver a relatively large payload (>9 kb, including intron-containing genomes), have the ability to transduce dividing and non-dividing cells, and stably integrate into the genome of a target cell to provide lifelong

correction to that cell and its progeny.<sup>10–13</sup> Further, the integration profile of LVs suggests that they are safer than gamma-retroviral vectors, and there have been no product-related malignant transformations reported to date with LVs used in clinical trials.<sup>14–16</sup> The promise of LV cell and gene therapy has led to the initialization of nearly 200 clinical trials, with notable successes in the treatment of hemoglobinopathies, primary immunodeficiencies, and leukemias.<sup>15,17–25</sup> In fact, LV-based cell and gene therapies have already been approved by the US Food and Drug Administration, Kymriah, and by the European Medicines Agency, Zynteglo. Furthermore, cancer immunotherapy, which currently includes the use of LV to modify T cell function, is an area of intense research. Thus, additional LV-based cellular therapies are likely to be approved in the future. However, the manufacturing of current Good Manufacturing Practices (cGMP)-grade LVs has been a challenge for early-phase clinical trials and is even more difficult for commercialization.<sup>26–28</sup> Thus, advances in industrial-scale vector manufacturing are required to meet current and future clinical needs for lentiviral-based cell and gene therapies.

Research into the production and design of LVs for gene therapy has been ongoing for over 20 years, and although incremental advancements have been made, the current methodologies need optimization.<sup>29–32</sup> Today, standard LVs are made using a third generation production system that relies on the transient transfection of HEK293T cells.<sup>33</sup> This transient transfection method can generate high-titer LVs free of replication-competent lentivirus. However, because of the adherent and serum-dependent nature of the HEK293T cell line, cGMP LV production is limited due to the need to use multi-stack plastic tissue culture vessels, for example, 10-stack Cell Factory

Received 31 August 2019; accepted 15 November 2019;  
<https://doi.org/10.1016/j.omtm.2019.11.011>.

<sup>4</sup>Present address: Metrum Research Group, Tariffville, CT 06081, USA

<sup>5</sup>Present address: Lyell Immunopharma, Seattle, WA 98109, USA

**Correspondence:** Robert E. Throm, Vector Development and Production Laboratory, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.

**E-mail:** [robert.throm@stjude.org](mailto:robert.throm@stjude.org)



systems, which increases the amount of handling, personnel and consumables costs, and production time. Furthermore, the use of animal-derived serum to maintain the HEK293T cell line increases the risk for contamination by adventitious viruses. In addition, obtaining large enough lots of serum can often be challenging and costly to acquire.

To address these challenges of industrial-scale cGMP-LV manufacturing, researchers have reported alternative means to produce LVs.<sup>27,34</sup> Many strategies use HEK293-derived cells that are adapted to grow in suspension with serum-free media (SFM), fixed-bed bioreactors, and stable producer cell lines.<sup>35–52</sup> However, these novel production schemes have been problematic for large-scale cGMP production for several reasons, including multiple handling steps, reduced titers, a limited production scale, continued use of tissue culture flasks, and reliance on animal-derived serum. To address these concerns, we adapted a HEK293T cell line to grow in suspension using a commercially available SFM. This newly derived cell line, SJ293TS, maintains the growth characteristics and LV productivity of the parental HEK293T cell line. We further improved the system's fitness for cGMP-manufacture of LVs by simplifying the cell manipulation steps in the manufacturing protocol and introduced an antibiotic-free (AF) selection marker on all transfected plasmids. We show that this new system produces equivalent amounts of vesicular stomatitis virus envelope glycoprotein (VSV-G)-pseudotyped LVs as are produced by conventional methods using adherent, serum-dependent HEK293T cells. Moreover, the SJ293TS system produces at least 10-fold higher LV titers than that provided by other suspension-adapted HEK293 cells, specifically Viral Production Cells and Expi293F cells. Importantly, we achieve a more than 2-fold increase in the recovery of LV transducing units (TUs) after downstream purification compared with historical data from HEK293T producer cells.<sup>53–55</sup> Finally, we demonstrate that LVs produced from SJ293TS cells can efficiently transduce human cells including T cells and CD34<sup>+</sup> cells.

## RESULTS

### Deriving the SJ293TS Cell Line

In order to convert the adherent HEK293T cell line to grow in suspension, we employed a commercially available SFM, Freestyle 293 Expression media (FS293). The cells were adapted by replacing the standard growth media, DMEM plus 10% fetal bovine serum (FBS) (D10), with FS293 supplemented with 10% FBS and seeded onto both non-tissue culture-treated and tissue culture-treated plates. Gradually, we reduced the amount of serum in the media at 1-week time intervals, and cells were passaged three times per week. After 4 weeks, the cells were growing solely in the presence of FS293. Cells that were successfully adapted directly using non-tissue culture-treated plates appeared to be less aggregated than those grown on tissue culture-treated plates; however, both approaches were ultimately successful in adapting HEK293T cells to grow in suspension without serum. The final adapted cell line, designated as SJ293TS, was then cultured in a shaking incubator to make a master cell bank. The cells were thawed, and their growth rate was determined by seeding the

cells at  $5 \times 10^5$  cells/mL followed by counting every 24 h for 2 days (Figure S1). SJ293TS cells doubled every  $23.4 \pm 2.7$  h and reached a cell density of up to  $3 \times 10^6$  cells/mL without compromising cell viability. For regular maintenance of the SJ293TS cell line, cultures were kept between  $3 \times 10^5$  and  $3 \times 10^6$  cells/mL and passaged every 2–3 days.


### Optimization of Transient Transfection Method

We assessed vector production using SJ293TS cells via our previously established transient transfection method.<sup>42,56</sup> Initially, we aimed to optimize transfection conditions using a simple GFP-expressing LV (vector CL40-MND-GFP) in 20-mL cultures in 125-mL shaker flasks for quick and easy readout. First, we tested the effect of cell density at the time of transfection. Based on our previous experience with adherent HEK293T cells as a starting point, where cell density is approximately  $1 \times 10^6$  cells/mL, we transfected SJ293TS cells at various densities ranging from 0.5 to  $3 \times 10^6$  cells/mL at two different concentrations of plasmid DNA, 0.55 and 1.1  $\mu\text{g}$  DNA per  $10^6$  cells. Twenty-four hours post transfection, the cells were pelleted by centrifugation and suspended in 20 mL of fresh media. Supernatants were collected 48 h post transfection and titered on HOS cells. Although LV production did not differ significantly among cells transfected at 1.1  $\mu\text{g}$  DNA per  $10^6$  cells, LV output using SJ293TS cells transfected with 0.55  $\mu\text{g}$  DNA per  $10^6$  cells was significantly impacted by seeding density, with the  $2 \times 10^6$  cells/mL density achieving the highest titers (Figure 1). Using a cell density fixed at  $2 \times 10^6$  cells/mL, we found that 0.55  $\mu\text{g}$  DNA/mL was optimal for achieving the highest titer yields (Figure S2).

Next, we examined the timing for optimal polyplex formation between polyethylenimine (PEI) and plasmid DNA under the conditions described in [Materials and Methods](#). A single master transfection mixture was made and incubated for up to 30 min. At various time points, an aliquot was taken from the transfection master mixture and used to transfect SJ293TS cells in a 20-mL culture. Although no significant differences were observed, peak vector production occurred when the incubation continued for 5 min, whereas longer incubation periods tended to decrease titer (Figure S3). Thus, all subsequent transfections of SJ293TS cells were performed after a 5-min incubation of PEI and plasmid DNA.

### Comparison of LV Production by SJ293TS Cells with Other HEK293-Based Cell Lines

To evaluate LV production in the suspension-adapted SJ293TS cell line, we compared 1-L productions of SJ293TS cells in 5-L shaker flasks against the parent HEK293T cells in 10-stack Cell Factory systems. For this comparison, three different clinically relevant LVs were produced: two containing shRNA<sup>mir</sup> against human BCL11A with fluorophores (vectors SJL118 and SJL121) and the other with an expression cassette for a second generation anti-CD19 chimeric antigen receptor (vector  $\alpha\text{CD19-CAR}$ ). Media were replaced 24 h post transfection as described above, and vector was harvested 24 h later. HEK293T titers were 1.8-, 1.4-, and 2-fold higher than SJ293TS cells (Table 1).



**Figure 1. Transfection Optimization of SJ293TS Cells to Produce Lentiviral Vectors**

(A and B) To optimize transfection conditions, we seeded SJ293TS cells at increasing cell densities and transfected with either (A) 0.55 or (B) 1.1 µg of total plasmid DNA per  $10^6$  cells by using a simple reporter lentiviral vector. \* $p = 0.0002$ , \*\* $p = 0.0167$ , \*\*\* $p = 0.0053$ , \*\*\*\* $p = 0.0193$ . No significant differences were detected among conditions tested in (B).  $n = 3$ . Data are expressed as the mean  $\pm$  the standard deviation.

There are few commercially available suspension HEK293 cell lines. We compared the SJ293TS cell line against two different HEK293-based suspension cell lines commercially available, namely, Expi293F cells and Viral Production Cells. All three cell lines were transfected, at the 20-mL scale, to produce CL40-MND-GFP. A master polyplex was formed, and an equal amount was distributed to each flask. In addition to GFP-LV, a more complex LV production, V5m3-Sardinia expressing the human  $\gamma$ -globin gene, was compared in a similar setting. The SJ293TS cell line produced 10- to 25-fold more TUs than either Viral Production Cells or Expi293F cells, regardless of vector. Statistical significance was reached only with the GFP-expressing vector, with  $p$  values of 0.0252 and 0.0239 in comparison with Viral Production Cells and Expi293F cells, respectively (Figure 2).

**Table 1. Titers of Either HEK293T or SJ293TS Cell-Derived Lentiviral Vectors Produced at 1-L Scale**

Producer Cell Line in Culture Vessel	Vector	TUs/mL <sup>a</sup>
HEK293T cells in Cell Factory	SJL118	$1.5 \times 10^8$
SJ293TS cells in 5-L shaker flask	SJL118	$8.2 \times 10^7$
HEK293T cells in Cell Factory	SJL121	$5.3 \times 10^8$
SJ293TS cells in 5-L shaker flask	SJL121	$3.7 \times 10^8$
HEK293T cells in Cell Factory Prep 1	$\alpha$ CD19-CAR	$2.00 \times 10^8$
HEK293T cells in Cell Factory Prep 2	$\alpha$ CD19-CAR	$2.00 \times 10^8$
SJ293TS cells in 5-L shaker flask	$\alpha$ CD19-CAR	$1.00 \times 10^8$


<sup>a</sup>One liter total volume, unprocessed supernatant titer.

### Improvements to SJ293TS LV Production Method

In order to improve the productivity and suitability of the SJ293TS cell line for cGMP manufacturing, we made modifications to the LV production process. Because there is growing concern using antibiotics for plasmid manufacturing, we looked for an alternative. An AF selection strategy, RNA-OUT, has been developed in which an approximately 150-bp cassette expresses a small antisense RNA against a counter-selectable marker expressed by the specialized bacterial host cell.<sup>57</sup> We replaced the  $\beta$ -lactamase expression cassette on our helper and transfer plasmids with RNA-OUT, which has the added benefit of reducing the size of the plasmid backbone. We also reduced the posttransfection cell culture handling by diluting transfected cells with an equal volume of fresh media rather than performing a full media exchange.

In the context of these changes, we also improved vector production by optimizing plasmid ratios used to transiently transfect SJ293TS cells. We found that a ratio of 14:4:2:0.25 of transfer vector:HIV-1 *gagpol*:Env:HIV-1 *rev*, compared with our previously used standard plasmid ratio of 12:6:2:0.25, led to a 1.7-fold increase in the titer of a pre-clinical LV (vector SJL644), which expresses a second generation anti-CD123 chimeric antigen receptor ( $p > 0.05$ ) and a reduction in the amount of HIV-1 p24 present in harvested supernatants ( $p > 0.05$ ) (Figures S4A and S4B). Interestingly, by using an estimate of  $10^4$  physical particles per picogram of HIV-1 p24, the physical particles per TU decreased significantly from an average of 319 to 170 ( $p = 0.0071$ ) (Figure S4B). Thus, the new plasmid ratio was implemented for all further SJ293TS vector productions.

The robustness and stability of our new manufacturing process was evaluated by continuously passaging SJ293TS cells in culture for over 4 months and performing periodic 1-L LV production using another pre-clinical vector that also expresses a second generation anti-CD123 chimeric antigen receptor (vector SJL643). To keep the total harvested volume at 1 L, 500 mL of SJ293TS cells was transfected at a cell density of  $2 \times 10^6$  cells/mL in a 5-L shaker flask. Titers from both unprocessed and purified material were highly reproducible, with respective averages of  $5.3 \pm 1.9 \times 10^7$  and  $1.2 \pm 0.4 \times 10^9$  TUs/mL (Figure 3A). When the same vector was produced by using



**Figure 2. Comparison of SJ293TS, Viral Production Cells, and Expi293F Cells as Lentiviral Vector Producer Cell Lines**


Production of either pCL40-MND-GFP (black bars) or pCL30-V5m3-Sardinia (gray bars) from SJ293TS, Viral Production Cells (VPCs), or Expi293F cells at the 20-mL scale. \* $p = 0.0252$ , \*\* $p = 0.0239$ .  $n = 3$ . Data are expressed as the mean  $\pm$  the standard deviation.

HEK293T cells in 10-stack Cell Factory systems using ampicillin-resistant plasmids, the titers obtained from SJ293TS cells were 1.8-fold higher, which was statistically significant,  $p = 0.02554$  (Figure 3B). Also, transfection of HEK293T cells consumed 2-fold more plasmid DNA than did SJ293TS cell transfection (1,012.5 versus 506.25  $\mu$ g, respectively), and due to several media exchanges, the use of 10-stack Cell Factory systems used 3-fold more media than did SJ293TS cells in 5-L shaker flasks.

Further characterization of a subset of these vector preparations indicated that the amounts of HIV-1 p24 in unprocessed supernatants and purified final LV preparations were between  $0.65 \pm 0.35$  and  $16.95 \pm 10.1$   $\mu$ g of HIV-1 p24 per mL, respectively (Table S1). The average number of physical particles per TU was not significantly different after downstream processing ( $p > 0.05$ ).

#### Downstream Processing of LVs Derived from SJ293TS Cells

During vector production, Benzonase, an RNA-DNA endonuclease, was added to producer cells 24 h post transfection to reduce plasmid and genomic DNA levels in vector supernatants. Upon harvest, 1-L LV preparations derived from SJ293TS cells were purified using scale-down cGMP-like processes. In brief, after clarification, LV harvests were subjected to anion-exchange chromatography, tangential flow filtration and 0.22  $\mu$ m filtration to reduce contaminating host cell protein and DNA, increase the concentration of LV TUs per milliliter, and ensure sterility of the final product (Figure 4). We applied these processing methods to 1-L research-grade LV preparations ( $n = 138$ ) at our institutional core facility. After 0.22  $\mu$ m filtration, the average overall recovery rate was  $55\% \pm 14\%$  of the total TUs present in the starting material. This represents an approximately 2-fold




**Figure 3. Consistent High-Titer Production of Clinically Relevant Lentiviral Vectors by SJ293TS Cells over Time and Comparison with HEK293T Cell-Derived Titers at 1-L Scale**

(A) Titers from unprocessed supernatants (solid gray line with circles) and purified final lentiviral vector preparations (black dashed line with triangles) from periodic production of VSV-G-pseudotyped SJL643 from SJ293TS cells continuously passaged over 4 months. (B) Total lentiviral vector transducing units (TUs) obtained from 1 L of transfected HEK293T cells or SJ293TS cells. \* $p = 0.02554$ .  $n = 3$  for HEK293T cells and  $n = 6$  for SJ293TS cells. Data are expressed as the mean  $\pm$  the standard deviation.

increase over previously published yields from adherent HEK293T serum-dependent cGMP-grade LV preparations, which ranged from 16% to 33% depending on the study.<sup>53,54</sup>

Four different 1-L LV preparations (before and after processing) were subjected to digital droplet PCR (ddPCR) analyses to detect contaminating plasmids as measured by the amplification of the RNA-OUT selection marker common to all transfected plasmids. Although plasmid DNAs were detected in all samples tested, the number of plasmid copies in the supernatant at harvest was reduced by 3–4 logs from the calculated plasmid input (at the time of transfection) ( $p \leq 0.001$ ) and did not change significantly after purification ( $p > 0.05$ ) (Figure S5). These data suggest that treatment of the vector harvest with a relatively low number of units of Benzonase during vector



**Figure 4. SJ293TS Lentiviral Vector Production Diagram**

Diagram outlining daily steps for the production and purification of lentiviral vectors from SJ293TS cells.

production significantly reduces contaminating plasmid content in the harvest and purified material.<sup>58</sup> As a consequence of this reduction, residual vector plasmid DNA is unlikely to confound vector titration. To test this, we performed ddPCR on genomic DNA from HOS cells transduced with either unconcentrated or concentrated LV preparations. No plasmid signal was detected by ddPCR in genomic DNA from cells harvested on either day 4 or day 7 (data not shown). Furthermore, calculated titers from these samples were comparable, with vector copy numbers (VCNs) ranging from 0.259 to 3.81. Interestingly, day 4 titers were only  $9\% \pm 11\%$  higher than day 7 titers (Table 2); thus, to accelerate LV titer determination, we performed ddPCR on HOS cells 4 days post transduction.

#### Suitability of SJ293TS-Derived LV for Clinical Gene and Cell Therapy

During our process development, we have produced clinically relevant LV, and we wanted to test how these vectors transduced target cell pop-

ulations, mainly human T cells or  $\text{CD}34^+$  HSCs. LV produced from the SJ293TS cell line efficiently transduced healthy donor-derived human T cells (Figure 5). Four distinct vector preparations containing two different second generation anti-CD123-CAR vectors, pSJL605 and pSJL643, were used to transduce primary human T cells at a MOI of 25. Seven days post transduction, all four T cell populations expressed high levels of anti-CD123 CAR on the surface and maintained levels of expansion and viability comparable with those of mock-transduced cells (Figures 5A and 5B). Of note, the average VCNs per cell were remarkably consistent between the four different LV batches, demonstrating the reproducibility of our production method (Figure 5C).

Next, we tested transduction efficiency on human  $\text{CD}34^+$  cells known for resistance to VSV-G-pseudotyped LVs. Similar to primary T cells, LV derived from SJ293TS cells efficiently transduced peripheral blood mobilized human  $\text{CD}34^+$  cells harvested from different healthy donors. To confirm that efficient transduction does not result from

**Table 2. HOS Cell Vector Copy Number at Days 4 and 7 Posttransduction**

Lentiviral Vector Sample	Day 4 VCN	Day 7 VCN
Prep 1 unconcentrated	2.62	2.32
Prep 1 final <sup>a</sup>	2.09	1.83
Prep 2 unconcentrated	1.63	1.42
Prep 2 final <sup>a</sup>	2.12	1.84
Prep 3 unconcentrated	2.48	2.31
Prep 3 final <sup>a</sup>	3.81	3.54
Prep 4 unconcentrated	0.259	0.206
Prep 4 final <sup>a</sup>	0.954	0.809
Prep 5 unconcentrated	1.32	1.30
Prep 5 final <sup>b</sup>	1.83	1.73
Prep 6 unconcentrated	1.83	1.55
Prep 6 final <sup>b</sup>	10.7	12.5

<sup>a</sup>Fifty-fold concentration post ion-exchange, ultra-filtration, and sterile filtration.

<sup>b</sup>Thirty-fold concentration by ultra-centrifugation.

one particular batch of LV, we produced multiple vector preparations of two different LVs, each expressing a small hairpin RNA along with a fluorophore from either the human hemoglobin locus control region DNA hypersensitivity sites HS2 and HS3 and with the  $\beta$ -globin promoter (vector SJL425) or the human glycophorin A promoter with a BCL11A enhancer (vector SJL319). CD34<sup>+</sup> cells were transduced at a MOI of 50 and subsequently plated into MethoCult in order to assess VCN from hematopoietic lineage cells. Twelve days later, MethoCult colonies were pooled together, and the average VCN was determined via ddPCR. SJL425 achieved VCNs of 0.89 and 2.71 on two different donors; two separate preparations of SJL319 exhibited VCNs of 0.76 and 1.05 on a third donor. The data are limited, but the nearly 3-fold VCN difference observed in MethoCult cultures using the SJL425 vector preparation likely reflects differences in donor permissivity.

### Baboon Endogenous Retroviral R-less Glycoprotein

An alternative envelope glycoprotein, the baboon endogenous retrovirus (BaEV), has been shown to greatly improve human B cell transduction otherwise resistant to VSV-G-pseudotyped LV.<sup>59</sup> Although promising, limitation of this envelope protein results from low titer partially due to syncytia formation during LV production in adherent HEK293T cells. We reasoned that vector production in suspension cells might alleviate syncytia formation and could lead to increased titers. To test whether SJ293TS cells might improve LV production pseudotyped with baboon endogenous retroviral R-less (BaEV-R-less), we compared titers of vectors produced by HEK293T and SJ293TS cells at similar scales using a GFP-expressing LV (vector CL40-MND-GFP). SJ293TS and HEK293T cells were transfected in culture volumes of 20 and 10 mL, respectively. However, because SJ293TS cells are transfected with half the concentration of DNA as HEK293T cells are, the total amount of DNA transfected into each cell line was identical. Thus, using the same amount of transfected DNA, SJ293TS cells provided 20-fold more TU than did HEK293T


cells (Figure 6). Furthermore, three different BaEV-R-less-pseudotyped LVs were produced from SJ293TS cells at the 1-L scale and concentrated 50-fold by using the downstream processing described above. Depending on the vector, titers ranged from 0.2 to  $2 \times 10^8$  TUs/mL with an average overall yield of  $33\% \pm 2.9\%$  from the starting supernatant. These data demonstrate that SJ293TS can be used to produce BaEV-R-less-pseudotyped LVs at titers higher than those of adherent HEK293T cells and can be purified using ion-exchange and tangential flow filtration.

### DISCUSSION

The use of LVs as a therapeutic modality is showing promise in many early clinical studies and has already achieved commercial approval for some lentiviral-based therapies.<sup>6,7,17–26,60</sup> Because most lentiviral gene and cellular therapies are currently in phase I/II clinical trials, demands for cGMP-grade LVs are achievable.<sup>24</sup> However, with the steady rise in the number of LV-based clinical trials and the expectation that more LV-based therapies will progress to late-stage clinical studies involving larger patient accruals, the production of cGMP-grade LVs may become a bottleneck for developing treatments. Indeed, most recent delay in commercialization partly stems from an unreliable vector supply chain.

The development of stable packaging and producer cell lines has been employed to mitigate some of the limitations of current LV production processes.<sup>39–43,45–52,61–63</sup> A common feature of these new systems is the reliance on adherent, serum-dependent cells, which may not be amenable to commercial-scale cGMP production. Further, although producer cell line stability and titers have been improved by tightly regulating the levels of cytotoxic components, these systems inherently introduce a level of complexity in producer cell maintenance and manipulation that could contaminate the final product. Finally, the development of stable LV producer cell lines requires a significant up-front investment in time to introduce the necessary elements and fully assess the ideal clonal cell line. Overall, these limitations are reflected by the relatively few clinical trials that utilize stable cell lines for their LV supply (ClinicalTrials.org: NCT03573700, NCT01512888, and NCT01306019).<sup>20,25</sup>

The most commonly used method for cGMP LV manufacturing is transient transfection of HEK293T cells to generate high-titer supernatants. This process has undergone extensive development over 20 years, and the flexibility of the system enables it to readily incorporate changes in vector design. cGMP manufacture of clinical-grade LVs is typically performed by using multi-stack trays due to the adherent and serum-dependent nature of the HEK293T cell line. This process is laborious, costly, and thus not conducive to scale-up. Instead, manufacturers often resort to scaling-out, which increases the number of production vessels and, consequently, the difficulty of vector production. To avoid these restrictions, HEK293 cells grown in suspension have been used instead of HEK293T cells to produce LVs with titers typically lower than those achieved with HEK293T cells.<sup>35,36,39,41</sup> Valkama et al.<sup>44</sup> reported using HEK293T cells in a fixed-bed bioreactor to produce LVs; however, the described method still required the initial expansion of cells on plastic



**Figure 5. Efficient Transduction of Healthy Human T Cells by SJ293TS-Derived Lentiviral Vector**

CD4<sup>+</sup> and CD8<sup>+</sup> human T cells from a single healthy donor were transduced with four separate lentiviral vector preparations derived from SJ293TS cells consisting of two different anti-CD123-CAR lentiviral vectors at a MOI of 25. (A–C) Seven days post transduction, the CD123 CAR expression was determined by flow cytometry analysis (A); the total number of cells, viability (B), and vector copy numbers (C) were also measured.

multi-trays before seeding the bioreactor. In 2011, Lesch et al.<sup>37</sup> produced LVs by transducing HEK293T cells with baculoviruses; however, this protocol included FBS and sodium butyrate during the production steps, which may complicate its integration into cGMP clinical-grade LV production. For a thorough review of various LV production systems, please see Merten et al.<sup>27</sup>

We describe a robust, cGMP-compatible LV production system using SJ293TS cells. By adapting HEK293T cells to grow in suspension using SFM, we avoid the drawbacks of using animal-derived products, such as serum, and the limits associated with the high cost and increased personnel handling time associated with tissue-culture-treated plasticware. Our production system relies on the well-defined, widely adapted, and highly productive HEK293T transient transfection method facilitating its use in cGMP-grade LV manufacturing. Further, because cGMP-grade reagents are a major expense in the production of clinical-grade LVs, our SJ293TS production system not only reduces overall consumables and media costs, including plasmid DNA, but provides for a nearly 2-fold increase in titer (Figure 3B) and post purification yields compared with previous historical data using adherent, serum-dependent HEK293T cells. The SJ293TS cell line is highly stable and can be continuously cultured for up to 4 months with no loss in the ability to produce high-titer LVs. These cells also produced high-titer alternative-envelope pseudotyped LVs such as the BaEV-R-less glycoprotein. Although SJ293TS cells have many advantages, as described above, over adherent, serum-depen-

dent HEK293T cells to produce LV, one potential disadvantage would be the requirement for current ongoing development programs to invest time in adopting a new LV manufacturing protocol. However, we believe that the benefits of this new LV production scheme outweigh any potential drawbacks.


A critical consideration for LV for clinical use is the ability to transduce clinically relevant target cells. Our data demonstrate that LVs derived from SJ293TS cells are capable of efficiently transducing both primary human CD34<sup>+</sup> cells from granulocyte-colony-stimulating factor mobilized peripheral blood of volunteers and healthy donor-derived peripheral T cells. Thus, our data suggest that the SJ293TS-production system represents a significant advancement in the production of LVs because it is stable, eliminates the need for animal-derived reagents, and is amenable to true scale-up manufacturing while increasing vector yields post purification. Future work will be focused on demonstrating this production scheme at the 5-L scale by using a stirred-tank bioreactor.

We have begun to establish a master cell bank derived from SJ293TS for future LV manufacturing at Children's GMP.

## MATERIALS AND METHODS

### Cell Lines

HEK293T and HOS cells were obtained from the American Type Culture Collection (ATCC CRL-11268 and CLR-1543, respectively) and



**Figure 6. Total BaEV-R-less-Pseudotyped Lentiviral Vector Transducing Units Produced by SJ293TS and HEK293T Cells**

SJ293TS cells produce 20-fold more TUs than HEK293T cells do when an equal amount of transfected DNA is used. \* $p = 0.0054$ .  $n = 4$ . Data are expressed as the mean  $\pm$  the standard deviation.

maintained in DMEM (Corning, Corning, NY, USA) supplemented with 10% FBS (Seradigm, Radnor, PA, USA) and 2 mM L-alanyl-L-glutamine (Corning) (D10) at 37°C with 5% CO<sub>2</sub>. Expi293F cells and Viral Production Cells were purchased and maintained in Expi293 Expression and LV-MAX production media, respectively (Thermo Fisher Scientific, Waltham, MA, USA). SJ293TS cells were maintained in Freestyle 293 Expression media (Thermo Fisher Scientific) and, along with Expi293F cells and Viral Production Cells, were cultured at 37°C with 8% CO<sub>2</sub> and shaking at 125 rpm.

### Plasmids

First, the plasmid, pCL20-MSCV-GFP, was retrofitted to RNA-OUT, replacing the 858-bp  $\beta$ -lactamase open reading frame with a 138-bp shRNA expression cassette for sucrose selection, by Nature Technology (Lincoln, NE, USA).<sup>57</sup> The resulting AF selection plasmid is named as pCL20-MSCV-GFP-AF2. The 2,988-bp *NheI*-*Sall* fragment from plasmids, pCAG-kGP1-1R, pCAG4-RTR2, and pCAG-VSVG, was removed and replaced with the 2,165-bp *NheI*-*Sall* fragment containing the RNA-OUT cassette from pCL20c-MSCV-GFP-AF2 to make pCAG-kGP1-1R-AF, pCAG4-RTR2-AF, and pCAG-VSVG-AF, respectively. The 2,753-bp *BsaAI*-*NheI* fragment from both pCAG4-RTR2 and pCAG4-RTR2-AF was replaced with a 720-bp synthetic DNA fragment consisting of the CMV promoter and the HIV-1 *rev* cDNA to make pCMV-Rev and pCMV-Rev-AF, respectively. The BaEV-R-less glycoprotein was synthesized as described in Girard-Gagnepain et al.<sup>64</sup> and cloned into pCAG4-Ampho by using *DraIII* and *PstI* to make pCAG4-BaEV-R-less. For pCAG4-BaEV-R-less-AF, a 2,512-bp *HinDIII*-*Sall* fragment in pCAG4-BaEV-R-less was replaced with a 1,693-bp *HinDIII*-*Sall* fragment

from pCAG4-VSVG-AF. Sequence files for all plasmids used in this study are available upon request.

### LV Production

Production of LV from adherent HEK293T cells was performed as described in Thom et al.,<sup>42</sup> except that pCAG-kGP1-1R (*gagpol*) and pCAG-VSVG (VSV-G) were substituted for pCAGG-HIVgpc (codon-optimized *gagpol*) and pHDM-G (VSV-G), respectively.<sup>56</sup> In brief, HEK293T cells were seeded to achieve ~80% confluency at the time of transfection, typically  $5 \times 10^6$  cells per 10-cm plate. The day of transfection, the media were exchanged. Transfection of cells in 10-cm plates was performed as follows: 12  $\mu$ g of transfer vector, 6  $\mu$ g of pCAG-kGP1-1R, 2  $\mu$ g of pCAG-VSVG, and either 2  $\mu$ g of pCAG4-RTR2 (*rev/tat*) or 0.25  $\mu$ g of pCMV-Rev (*rev*). When SJ293TS cells were used to produce LV in 20-mL cultures, cells were seeded at  $1 \times 10^6$  cells/mL. The next day, cells were transfected with the specified LV transfer plasmid and the helper plasmids as follows: 14  $\mu$ g of transfer vector, 4  $\mu$ g of pCAG-kGP1-1R, 2  $\mu$ g of pCAG-VSVG, and either 2  $\mu$ g pCAG4-RTR2 or 0.25  $\mu$ g pCMV-Rev. pCAG4-RTR2, which expresses HIV-1 *rev* and *tat*, was used to produce LVs as part of our core institutional services and in Figures 1, S2, and S3, Table 1, and pCL30-V5m3-Sardinia in Figure 2, whereas pCMV-Rev was used to produce LVs in all other data presented. Substitution of pCMV-Rev for pCAG4-RTR2 slightly reduced the total amount of plasmid DNA in the transfection of SJ293TS cells from 0.55  $\mu$ g per  $1 \times 10^6$  cells to 0.50625  $\mu$ g per  $1 \times 10^6$  cells. All transfections were performed using PEIpro (Polyplus Transfection, Strasbourg, France). Transfection reagents were scaled up proportionally depending on the scale of vector production. Before mixing, plasmid DNA was diluted in PBS (Corning) to 40  $\mu$ g/mL, and PEIpro was diluted to 80  $\mu$ g/mL in PBS. The transfection mixture was then incubated for approximately 5 min before being added directly to the cell culture. Twenty-four hours post transfection, the media were replaced or, in some instances, transfected SJ293TS cells were diluted with an equal volume of fresh media. At the same time, Benzonase was added to the cell culture to achieve a final concentration of 6.25 U/mL. Vector supernatants were harvested 48 h post transfection and clarified by centrifugation to remove cells, filtration through 0.45- and 0.22- $\mu$ m filters, and either subjected to further purification or stored at -80°C before titration. Production of 1-L LV preparations by adherent HEK293T cells was made using 10-stack Cell Factory systems (Thermo Fisher Scientific). RNA-OUT-containing helper plasmids were always used together, and the plasmid pCAG-VSVG-AF was substituted with pCAG-BaEV-R-less-AF to produce BaEV-R-less pseudotyped LVs. For Expi293F cells and Viral Production Cells, vector was harvested at the optimal 72 h post transfection.

For downstream processing, LV containing supernatant was adjusted to 300 mM NaCl with 50 mM Tris (pH 8.0) before being loaded onto a 5-mL Mustang Q XT5 ion-exchange capsule (Pall Life Sciences, Port Washington, NY, USA) per the manufacturer's instructions using an Akta Avant chromatography system (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). The column was then washed with 10 column volumes of 300 mM NaCl with 50 mM Tris (pH 8.0), and LV particles



were eluted from the column by using 2 M NaCl, 50 mM Tris (pH 8.0). The eluate was diluted 5-fold with PBS and diafiltrated twice in PBS using a Vivaflow 50 with a 100,000 molecular weight cutoff (Sartorius AG, Göttingen, Germany) according to the manufacturer's instructions before a final diafiltration was performed in X-VIVO 10 or X-VIVO 15 media (Lonza) to achieve a final concentration of about 50-fold from the starting material. The vector was then 0.22  $\mu$ M filtered, aliquoted, and stored at  $-80^{\circ}\text{C}$  before being titrated.

#### HIV-1 p24 ELISA

HIV-1 p24 determination was performed using RETROtek HIV-1 p24 Antigen ELISA kit (ZeptoMetrix Corporation, Buffalo, NY, USA) according to the manufacturer's instructions.

#### LV Copy Number Determination and Plasmid Detection

To determine viral titers, we seeded HOS cells at a density of  $1 \times 10^5$  cells/well of a six-well plate at least 2 h before transduction. Vector aliquots were thawed at room temperature, serially diluted, and added to HOS cells in the presence of Polybrene (5–8  $\mu\text{g}/\text{mL}$ ; MilliporeSigma, Burlington, MA, USA) in a total volume of 1 mL. The next day, the media were exchanged. For fluorescent-reporter vectors, transduced HOS cells were analyzed 3–4 days post transduction by flow cytometry. For vectors titrated by PCR, transduced HOS cells were cultured until day 4 or 7, when genomic DNA was isolated by using the Quick-DNA Miniprep kit (Zymo Research, Irvine, CA, USA). To determine the VCN, genomic DNA was digested with *MspI* and used as a template in PCR by using a ddPCR instrument (QX200; Bio-Rad, Carlsbad, CA, USA). The following primer-probe sets were used to amplify the HIV *psi* sequence and the endogenous control gene, *RPP30*, 5'-ACTTGAAAGCGAAAGGGAAAC-3', 5'-CACCCATCTCTCCTTCTAGCC-3' and probe 5'-56-FAM-AGCTCTCTC-ZEN-GACGCAGGACTCGGC-3IABkFQ-3' and 5'-GCGGCTGTCTCCACAAGT-3', 5'-GATTTGGACCTGCGAGCG-3' and probe 5'-5HEX-CTGACC TGA-ZEN-AGGCTCT-3IABkFQ-3', respectively. Vector titers and copy number were determined by calculating the number of copies of HIV *psi* to every two copies of *RPP30*, multiplied by the number of cells transduced, and if necessary, multiplied by the dilution factor.

Transfected RNA-OUT plasmids were detected via ddPCR using the following primer-probe set: 5'-GACGCTCAGTGAACGAAA-3', 5'-AACAAGATGTGCGAACTCGATA-3', and 5'-56-FAM-ACACGACTC-ZEN-TCTTTACCAATTCTACCACC-3IABkFQ-3'.

#### hCD34<sup>+</sup> Cell Transduction and Colony Forming Unit Assay

The St. Jude Human Applications Laboratory or Key Biologics (Memphis, TN, USA) purified CD34<sup>+</sup> cells from granulocyte-colony-stimulating factor mobilized peripheral blood of healthy volunteers. CD34<sup>+</sup> cells were cultured in X-VIVO 10 (Lonza, Walkersville, MD, USA) with 100 ng/mL of stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (FLT3-ligand), and thrombopoietin (TPO) (CellGenix, Freiburg, Germany), 50 U/mL of penicillin/streptomycin (Corning), and 2 mM L-alanyl-L-glutamine (Corning). Cells were primed overnight in media at a density of  $1 \times 10^6$  cells/mL and seeded at a density of  $2 \times 10^6$  cells/mL at the time of transduction with vector

in the presence of 8  $\mu\text{g}/\text{mL}$  protamine sulfate (St. Jude Children's Research Hospital pharmacy), 6.25 U/mL of Benzonase (Millipore-Sigma), 1% recombinant human serum albumin (Grifols Biologics, Los Angeles, CA, USA), and 10  $\mu\text{M}$  prostaglandin E2 (Cayman Chemical, Ann Arbor, MI, USA). Twenty-four hours post transduction, cells were seeded in MethoCult H4434 Classic (STEMCELL Technologies, Vancouver, BC, Canada), and colonies were pooled on post transduction day 12 for analysis by ddPCR.

#### T Cell Transduction

Healthy donor-derived human peripheral blood apheresis cells were purchased from Key Biologics. The cells were labeled with anti-CD4/CD8 microbeads, and CD4<sup>+</sup>/CD8<sup>+</sup> T cells were purified by using the CliniMACS system (Miltenyi Biotec, Bergisch Gladbach, Germany). CD4<sup>+</sup> and CD8<sup>+</sup> T cells from peripheral blood mononuclear cells were suspended in X-VIVO 15 media with 5% human AB serum (Valley Biomedicals, Winchester, VA, USA) and 10 ng/mL of recombinant human IL-7 and IL-15 (Miltenyi Biotec) (X-VIVO 15–5% HSA/IL-7/IL-15, hereafter). Then, cells were activated with T Cell TransAct (Miltenyi Biotec) according to the manufacturer's protocol in six-well plates (Thermo Fisher Scientific) at  $37^{\circ}\text{C}$  with 5% CO<sub>2</sub> for 24 h. The activated T cells were washed and suspended in X-VIVO 15–5% HSA/IL-7/IL-15 followed by transduction with four different batches of anti-CD123 chimeric antigen receptor-expressing vectors at a MOI of 25 in a total volume of 1 mL. After 22 h of transduction, the cells were transferred to a G-Rex plate (Wilson Wolf, St. Paul, MN, USA) and incubated in 30 mL of X-VIVO 15–5% HSA/IL-7/IL-15. CD123-specific chimeric antigen receptor-expressing T cell expression, viability, and expansion were determined 5 days post transduction.

#### Flow Cytometry

A CytoFlex (Beckman Coulter, Brea, CA, USA) instrument was used to acquire immunofluorescence data. FlowJo v.10 (FlowJo, Ashland, OR, USA) was used for data analysis and graphic representation. Genetically modified anti-CD123 chimeric antigen receptor-expressing T cells were detected by using a recombinant human IL-3RA/CD123 Fc chimera (Abcam, Cambridge, UK) and phycoerythrin (PE)-conjugated goat anti-human Fc-IgG (immunoglobulin G; Southern Biotech, Birmingham, AL, USA). We used 7-aminoactinomycin D (7-AAD) (TONBO Biosciences, San Diego, CA, USA) to distinguish live cells from dead cells. Cells were collected and washed twice with PBS (Corning) before CD123 Fc Chimera was added. The cells were incubated for 30 min at  $4^{\circ}\text{C}$  in the dark, washed twice, and incubated with PE-conjugated goat anti-human Fc-IgG in PBS with 2% FBS (fluorescence-activated cell sorting [FACS] buffer) for 30 min at  $4^{\circ}\text{C}$  in the dark. The cells were washed twice and then suspended with FACS buffer containing 7-AAD before analysis.

#### Statistical Analyses

Statistical analysis was performed using R version 3.3.3 (<https://www.r-project.org/>). A t test or a one-way ANOVA followed by Tukey's post hoc analysis was used for analyses. Significance was defined as a p value  $<0.05$ .

## SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.omtm.2019.11.011>.

## AUTHOR CONTRIBUTIONS

M.B., J.K.R., C.-C.W., B.F., F.F., B.H.Y., S.D., M.M.W., Y.-I.K., and J.M. developed methods, performed experiments, and analyzed data. J.K.R. conducted all statistical analyses. S.Z., M.M.W., B.R., and R.E.T. conceived experiments and interpreted data. R.E.T. wrote the manuscript. All authors read and approved the final manuscript.

## CONFLICTS OF INTEREST

The authors declare no competing interests.

## ACKNOWLEDGMENTS

This study was supported with funding from the National Heart, Lung, and Blood Institute (grant PO1 HL-53749), the Assisi Foundation of Memphis, and the American Lebanese Syrian Associated Charities.

## REFERENCES

- Zheng, Y., Yu, F., Wu, Y., Si, L., Xu, H., Zhang, C., Xia, Q., Xiao, S., Wang, Q., He, Q., et al. (2015). Broadening the versatility of lentiviral vectors as a tool in nucleic acid research via genetic code expansion. *Nucleic Acids Res.* *43*, e73.
- Ranzani, M., Annunziato, S., Calabria, A., Brasca, S., Benedicenti, F., Gallina, P., Naldini, L., and Montini, E. (2014). Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies. *Mol. Ther.* *22*, 2056–2068.
- Ranzani, M., Cesana, D., Bartholomae, C.C., Sanvito, F., Pala, M., Benedicenti, F., Gallina, P., Sergi, L.S., Merella, S., Bulfone, A., et al. (2013). Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. *Nat. Methods* *10*, 155–161.
- Mak, A.B., and Moffat, J. (2012). A versatile lentiviral expression system to identify mammalian protein-protein interactions. *Methods* *57*, 409–416.
- Moffat, J., Grueneberg, D.A., Yang, X., Kim, S.Y., Kloepfer, A.M., Hinkle, G., Piqani, B., Eisenhaure, T.M., Luo, B., Grenier, J.K., et al. (2006). A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. *Cell* *124*, 1283–1298.
- Naldini, L. (2019). Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. *EMBO Mol. Med.* *11*, e9958.
- Kumar, S.R., Markusic, D.M., Biswas, M., High, K.A., and Herzog, R.W. (2016). Clinical development of gene therapy: results and lessons from recent successes. *Mol. Ther. Methods Clin. Dev.* *3*, 16034.
- Levine, B.L., Miskin, J., Wonnacott, K., and Keir, C. (2016). Global Manufacturing of CAR T Cell Therapy. *Mol. Ther. Methods Clin. Dev.* *4*, 92–101.
- Hu, B., Tai, A., and Wang, P. (2011). Immunization delivered by lentiviral vectors for cancer and infectious diseases. *Immunol. Rev.* *239*, 45–61.
- Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M., and Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. *Science* *272*, 263–267.
- Kumar, M., Keller, B., Makalou, N., and Sutton, R.E. (2001). Systematic determination of the packaging limit of lentiviral vectors. *Hum. Gene Ther.* *12*, 1893–1905.
- Lewis, P.F., and Emlen, M. (1994). Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. *J. Virol.* *68*, 510–516.
- Ramezani, A., and Hawley, R.G. (2002). Overview of the HIV-1 Lentiviral Vector System. *Curr. Protoc. Mol. Biol. Chapter 16*, Unit 16.21.
- Modlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M.H., Schambach, A., Charrier, S., Galy, A., Thrasher, A.J., et al. (2009). Insertional trans-formation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. *Mol. Ther.* *17*, 1919–1928.
- McGarrity, G.J., Hoyah, G., Winemiller, A., Andre, K., Stein, D., Blick, G., Greenberg, R.N., Kinder, C., Zolopa, A., Binder-Scholl, G., et al. (2013). Patient monitoring and follow-up in lentiviral clinical trials. *J. Gene Med.* *15*, 78–82.
- Cesani, M., Plati, T., Lorioli, L., Benedicenti, F., Redaelli, D., Dionisio, F., Biasco, L., Montini, E., Naldini, L., and Biffi, A. (2015). Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting. *Gene Ther.* *22*, 496–502.
- Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. *N. Engl. J. Med.* *371*, 1507–1517.
- Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., Bagg, A., Marcucci, K.T., Shen, A., Gonzalez, V., et al. (2015). Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci. Transl. Med.* *7*, 303ra139.
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010). Transfusion independence and HMG2A activation after gene therapy of human  $\beta$ -thalassaemia. *Nature* *467*, 318–322.
- De Ravin, S.S., Wu, X., Moir, S., Anaya-O'Brien, S., Kwatema, N., Littel, P., Theobald, N., Choi, U., Su, L., Marquesen, M., et al. (2016). Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. *Sci. Transl. Med.* *8*, 335ra57.
- Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. *Science* *341*, 1233158.
- Eichler, F., Duncan, C., Musolino, P.L., Orchard, P.J., De Oliveira, S., Thrasher, A.J., Armant, M., Dansereau, C., Lund, T.C., Miller, W.P., et al. (2017). Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. *N. Engl. J. Med.* *377*, 1630–1638.
- Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M.P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M.C., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. *Science* *341*, 1233151.
- Ginn, S.L., Amaya, A.K., Alexander, I.E., Edelstein, M., and Abedi, M.R. (2018). Gene therapy clinical trials worldwide to 2017: An update. *J. Gene Med.* *20*, e3015.
- Mamcarz, E., Zhou, S., Lockey, T., Abdelsamed, H., Cross, S.J., Kang, G., Ma, Z., Condori, J., Dowdy, J., Triplett, B., et al. (2019). Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. *N. Engl. J. Med.* *380*, 1525–1534.
- Milone, M.C., and O'Doherty, U. (2018). Clinical use of lentiviral vectors. *Leukemia* *32*, 1529–1541.
- Merten, O.W., Hebben, M., and Bovolenta, C. (2016). Production of lentiviral vectors. *Mol. Ther. Methods Clin. Dev.* *3*, 16017.
- McCarron, A., Donnelly, M., McIntyre, C., and Parsons, D. (2016). Challenges of up-scaling lentivirus production and processing. *J. Biotechnol.* *240*, 23–30.
- Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L., and Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nat. Biotechnol.* *15*, 871–875.
- Kim, V.N., Mitrophanou, K., Kingsman, S.M., and Kingsman, A.J. (1998). Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. *J. Virol.* *72*, 811–816.
- Reiser, J., Harmison, G., Kluepfel-Stahl, S., Brady, R.O., Karlsson, S., and Schubert, M. (1996). Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. *Proc. Natl. Acad. Sci. USA* *93*, 15266–15271.
- Kuroda, H., Kutner, R.H., Bazan, N.G., and Reiser, J. (2009). Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. *J. Virol. Methods* *157*, 113–121.
- Dull, T., Zufferey, R., Kelly, M., Mandel, R.J., Nguyen, M., Trono, D., and Naldini, L. (1998). A third-generation lentivirus vector with a conditional packaging system. *J. Virol.* *72*, 8463–8471.

34. Segura, M.M., Mangion, M., Gaillet, B., and Garnier, A. (2013). New developments in lentiviral vector design, production and purification. *Expert Opin. Biol. Ther.* *13*, 987–1011.
35. Segura, M.M., Garnier, A., Durocher, Y., Coelho, H., and Kamen, A. (2007). Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. *Biotechnol. Bioeng.* *98*, 789–799.
36. Ansoorge, S., Lanthier, S., Transfiguracion, J., Durocher, Y., Henry, O., and Kamen, A. (2009). Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. *J. Gene Med.* *11*, 868–876.
37. Lesch, H.P., Laitinen, A., Peixoto, C., Vicente, T., Makkonen, K.E., Laitinen, L., Pikkarainen, J.T., Samaranyake, H., Alves, P.M., Carrondo, M.J., et al. (2011). Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors. *Gene Ther.* *18*, 531–538.
38. Witting, S.R., Li, L.H., Jasti, A., Allen, C., Cornetta, K., Brady, J., Shivakumar, R., and Peshwa, M.V. (2012). Efficient large volume lentiviral vector production using flow electroporation. *Hum. Gene Ther.* *23*, 243–249.
39. Sanber, K.S., Knight, S.B., Stephen, S.L., Bailey, R., Escors, D., Minshull, J., Santilli, G., Thrasher, A.J., Collins, M.K., and Takeuchi, Y. (2015). Construction of stable packaging cell lines for clinical lentiviral vector production. *Sci. Rep.* *5*, 9021.
40. Broussau, S., Jabbour, N., Lachapelle, G., Durocher, Y., Tom, R., Transfiguracion, J., Gilbert, R., and Massie, B. (2008). Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. *Mol. Ther.* *16*, 500–507.
41. Manceur, A.P., Kim, H., Misis, V., Andreev, N., Dorion-Thibaudeau, J., Lanthier, S., Bernier, A., Tremblay, S., Gélinas, A.M., Broussau, S., et al. (2017). Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines. *Hum. Gene Ther. Methods* *28*, 330–339.
42. Throm, R.E., Ouma, A.A., Zhou, S., Chandrasekaran, A., Lockey, T., Greene, M., De Ravin, S.S., Moayeri, M., Malech, H.L., Sorrentino, B.P., and Gray, J.T. (2009). Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. *Blood* *113*, 5104–5110.
43. Wielgosz, M.M., Kim, Y.S., Carney, G.G., Zhan, J., Reddivari, M., Coop, T., Heath, R.J., Brown, S.A., and Nienhuis, A.W. (2015). Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy. *Mol. Ther. Methods Clin. Dev.* *2*, 14063.
44. Valkama, A.J., Leinonen, H.M., Lipponen, E.M., Turkki, V., Malinen, J., Heikura, T., Ylä-Herttua, S., and Lesch, H.P. (2018). Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor. *Gene Ther.* *25*, 39–46.
45. Ikeda, Y., Takeuchi, Y., Martin, F., Cosset, F.L., Mitrophanous, K., and Collins, M. (2003). Continuous high-titer HIV-1 vector production. *Nat. Biotechnol.* *21*, 569–572.
46. Cockrell, A.S., Ma, H., Fu, K., McCown, T.J., and Kafri, T. (2006). A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. *Mol. Ther.* *14*, 276–284.
47. Xu, K., Ma, H., McCown, T.J., Verma, I.M., and Kafri, T. (2001). Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. *Mol. Ther.* *3*, 97–104.
48. Marin, V., Stornaiuolo, A., Piovani, C., Corna, S., Bossi, S., Pema, M., Giuliani, E., Scavullo, C., Zucchelli, E., Bordinon, C., et al. (2016). RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope. *Mol. Ther. Methods Clin. Dev.* *3*, 16033.
49. Stornaiuolo, A., Piovani, B.M., Bossi, S., Zucchelli, E., Corna, S., Salvatori, F., Mavilio, F., Bordinon, C., Rizzardi, G.P., and Bovolenta, C. (2013). RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy. *Hum. Gene Ther. Methods* *24*, 228–240.
50. Farson, D., Witt, R., McGuinness, R., Dull, T., Kelly, M., Song, J., Radeke, R., Bukovsky, A., Consiglio, A., and Naldini, L. (2001). A new-generation stable inducible packaging cell line for lentiviral vectors. *Hum. Gene Ther.* *12*, 981–997.
51. Ni, Y., Sun, S., Oparaocha, I., Humeau, L., Davis, B., Cohen, R., Binder, G., Chang, Y.N., Slepushkin, V., and Dropulic, B. (2005). Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. *J. Gene Med.* *7*, 818–834.
52. Klages, N., Zufferey, R., and Trono, D. (2000). A stable system for the high-titer production of multiply attenuated lentiviral vectors. *Mol. Ther.* *2*, 170–176.
53. Greene, M.R., Lockey, T., Mehta, P.K., Kim, Y.S., Eldridge, P.W., Gray, J.T., and Sorrentino, B.P. (2012). Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line. *Hum. Gene Ther. Methods* *23*, 297–308.
54. Merten, O.W., Charrier, S., Laroudie, N., Fauchille, S., Dugué, C., Jenny, C., Audit, M., Zanta-Boussif, M.A., Chautard, H., Radrizzani, M., et al. (2011). Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. *Hum. Gene Ther.* *22*, 343–356.
55. Bandeira, V., Peixoto, C., Rodrigues, A.F., Cruz, P.E., Alves, P.M., Coroadinha, A.S., and Carrondo, M.J. (2012). Downstream processing of lentiviral vectors: releasing bottlenecks. *Hum. Gene Ther. Methods* *23*, 255–263.
56. Hanawa, H., Persons, D.A., and Nienhuis, A.W. (2005). Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors. *J. Virol.* *79*, 8410–8421.
57. Luke, J., Carnes, A.E., Hodgson, C.P., and Williams, J.A. (2009). Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. *Vaccine* *27*, 6454–6459.
58. Ausubel, L.J., Hall, C., Sharma, A., Shakeley, R., Lopez, P., Quezada, V., Couture, S., Laderman, K., McMahon, R., Huang, P., et al. (2012). Production of CGMP-Grade Lentiviral Vectors. *Bioprocess Int.* *10*, 32–43.
59. Levy, C., Fusil, F., Amirache, F., Costa, C., Girard-Gagnepain, A., Negre, D., Bernadin, O., Garaulet, G., Rodriguez, A., Nair, N., et al. (2016). Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCID $\gamma$ <sup>-/-</sup> mice. *J. Thromb. Haemost.* *14*, 2478–2492.
60. Bach, P.B., Giral, S.A., and Saltz, L.B. (2017). FDA Approval of Tisagenlecleucel: Promise and Complexities of a \$475 000 Cancer Drug. *JAMA* *318*, 1861–1862.
61. Pacchia, A.L., Adelson, M.E., Kaul, M., Ron, Y., and Dougherty, J.P. (2001). An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. *Virology* *282*, 77–86.
62. Sparacio, S., Pfeiffer, T., Schaal, H., and Bosch, V. (2001). Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. *Mol. Ther.* *3*, 602–612.
63. Kafri, T., van Praag, H., Ouyang, L., Gage, F.H., and Verma, I.M. (1999). A packaging cell line for lentivirus vectors. *J. Virol.* *73*, 576–584.
64. Girard-Gagnepain, A., Amirache, F., Costa, C., Lévy, C., Frecha, C., Fusil, F., Nègre, D., Lavillette, D., Cosset, F.L., and Verhoeven, E. (2014). Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. *Blood* *124*, 1221–1231.